REG - Yourgene Health PLC - Open Day and advance notice of AGM

Yourgene HealthAnnouncement

16/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220816:nRSP0969Wa&default-theme=true

RNS Number : 0969W  Yourgene Health PLC  16 August 2022

Yourgene Health plc

("Yourgene", the "Company" or the "Group")

 

Open Day and advance notice of AGM

 

Manchester, UK - 16 August 2022: Yourgene (AIM: YGEN), the international
molecular diagnostics group, will be hosting an Open Day at its new facilities
on Manchester Science Park, Manchester, UK on Tuesday 27 September 2022 from
3pm to 6pm, welcoming shareholders, analysts and other interested
stakeholders.

 

The Open Day will follow immediately after the Company's Annual General
Meeting ("AGM") which will be held from 2pm-3pm on the same day. The formal
Notice of Meeting for the AGM will be issued shortly and confirmed by separate
announcement.

 

The Open Day will provide an opportunity to meet the Senior Management team,
take a tour of the Company's new facilities and laboratories and familiarise
themselves with the Company's genomic technology and service solutions.

 

All Open Day attendees must register through Walbrook PR to reserve a space.
For more information and to register, please email yourgene@walbrookpr.com
(mailto:yourgene@walbrookpr.com)  or telephone Walbrook PR on +44 (0)20 7933
8780.

 

Participation protocols for the AGM will be provided to shareholders and
notified separately in due course, but Open Day attendees can also provide
advance notice of AGM attendance to Walbrook when they register for the Open
Day.

 

As previously indicated in the Audited Final Results release dated 27 July
2022, an electronic copy of the Company's Annual Report and Accounts for the
financial year ended 31 March 2022 is available online at
https://www.yourgene-health.com/investors/key-documents/financial-reports
(https://www.yourgene-health.com/investors/key-documents/financial-reports)

 

 

 Yourgene Health plc                                Tel: +44 (0)161 669 8122

 Lyn Rees, Chief Executive Officer                  investors@yourgene-health.com (mailto:investors@yourgene-health.com)
 Barry Hextall, Chief Financial Officer
 Joanne Cross, Director of Marketing

 Cairn Financial Advisers LLP (NOMAD)               Tel: +44 (0)20 7213 0880
 Liam Murray / James Caithie / Ludovico Lazzaretti

 Singer Capital Markets (Corporate Broker)          Tel: +44 (0)20 7496 3000
 Aubrey Powell / Tom Salvesen / George Tzimas

 Walbrook PR Ltd (Media and Investor Relations)     Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
                                                    (mailto:yourgene@walbrookpr.com)
 Lianne Applegarth / Alice Woodings                 Mob: 07584 391 303 / 07407 804 654

 

About Yourgene Health

 

Yourgene Health is an international molecular diagnostics group which develops
integrated genomic technologies and services enabling precision medicine. The
group works in partnership with global leaders in DNA technology to advance
diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and
accurate molecular diagnostic solutions, for reproductive health, precision
medicine and now infectious diseases. The Group's flagship products include
non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests,
and a recent extension into the oncology space with DPYD genotyping.

 

The Yourgene Genomic Services team works with healthcare professionals,
researchers and pharmaceutical organisations to support and accelerate
scientific advances in genomic medicine. The division's specialist services
guide decisions about abnormalities, hereditary risk and treatment in addition
to providing novel insights in research and discovery. Accredited clinical
services are provided in Oncology and Reproductive Health within the UK and
worldwide. The team of scientific experts offer consultative services to help
guide partners in selecting the right technology and approach for their
applications.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation
technology company based in Vancouver, Canada, enabling the Company to extend
its offering and IP portfolio in the DNA sample preparation sector. The
acquisition increased Yourgene's geographical penetration into the US and
Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei,
Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM
market under the ticker "YGEN". For more information visit
www.yourgene-health.com (http://www.yourgene-health.com/) and follow us on
twitter @Yourgene_Health.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFFFFLTEIELIF